TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mother's depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose (MTD) of OPB-111077
Endpoint domain: Adverse events/effects
Primary endpoint: Change in management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Central Corneal Endothelial Cell Density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with at Least One Grade 3 or Higher Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Adverse Event Leading to TAK-079 Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first occurrence of MACE
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in speech and communication
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Number of participants suffering post-operative cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pericardial effusion recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedural related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Reduction in Number of Seizures Greater Than or Equal to 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Reduction in Number of Seizures Greater Than or Equal to 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Seizure Free Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of follow-up to an outpatient provider within 21 days of SNF discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of appropriate monitoring for selected high risk medications at 30 days from the time of SNF discharge
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of adverse drug events (ADEs) 45 days after discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of SNF readmission and emergency department (ED) within 30 days of discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in RDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuffless Blood Pressure performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroprevalence of Avian Influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression of Diabetic Retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Development of significant Macular Edema (ME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Moderate visual loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum tolerated dose (MTD) and recommended phase two dose (RPTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobilization of progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological Response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of opioids and analgesic medications consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in endothelial progenitor cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic Evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rebleeding rate requiring operative intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Short interval Intracortical Inhibition (SICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anterior corneal curvature development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior corneal curvature development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thinnest corneal pachymetry development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected distance visual acuity development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With Abnormal Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Patients With Abnormal Liver Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Deterioration Resulting in Healthcare Review
Endpoint domain: Adverse events/effects
Primary endpoint: Intra-Abdominal Pressure (IAP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum anti-p53 antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in T-TAS parameters (AR-chip, PL-chip)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best Response as Measured by CT, Bone Scans, and Clinical Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Toxicity by Clinical Evaluation From First Dose to 30 Days After Last Dose
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative costs over 90-days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Knowledge gaps about oral anticoagulation therapy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of NSVTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evolution of the arrhythmic substrate by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adequate understanding of algorithmic feedback
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Successful completion of frequent and risk-related tasks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Relative thickness as assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-micturition activity during normal bladder filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinically Significant Disease Reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth pain and hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical phenotype assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FRC measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ORGN001
Endpoint domain: Adverse events/effects
Primary endpoint: Hearing Handicap Inventory for the Elderly (HHIE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HbA1c at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in minutes of sedentary time per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in minutes of light physical activity per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pediatric post-operative mortality
Endpoint domain: Mortality/survival
Primary endpoint: PrEP uptake changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention feasibility changes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preterm birth prediction
Endpoint domain: Mortality/survival
Primary endpoint: Composite incidence of new acute kidney injury (AKI), new hypotension, and new shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Score on SKAMP rating scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Liver Decompensation
Endpoint domain: Mortality/survival
Primary endpoint: Time to fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beginning of empiric antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite Pharmacokinetic parameter for Prednisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative DSA by Luminex beads or ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lack of C4d deposition in peritubular capillary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of complete response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycemia Fear Survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brain receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting hepatic glycogen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting hepatic lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Digit Symbol Substitution Test (DSST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: GerdQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Histological grading improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Completed Fields
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Forearm Blood Flow Responses to Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Forearm Blood Flow Responses to Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Change in ATP Release to Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ATP Release to Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steady State Area Under the Concentration-Time Curve (AUC0-12) of Oseltamivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Oseltamivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatty acid profile of serum lipid fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Venous distension of > 27%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease specific-quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient reported outcomes on urea cycle relevant dimensions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Applied cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: height of the peri-implant mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: width of the peri-implant mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Global quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-op opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Y-BOCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of spermatozoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Syndrome metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic Parameter AUC(0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure and Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse oximetry levels in healthy newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dislocation of the femoral nerve catheter
Endpoint domain: Adverse events/effects
Primary endpoint: Median length of postoperative hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Treatment-related Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients treated by antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal pulse oximetry oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breaths per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of AZD7451
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pH at 1+ hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Pain Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of useful alarms
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: health centre visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Degree of intracranial artery vessel wall enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neonatal cord blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: alcohol use
Endpoint domain: Adverse events/effects
Primary endpoint: marijuana use
Endpoint domain: Adverse events/effects
Primary endpoint: sexually transmitted infection
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Reported 7-day Point Prevalence Abstinence From Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: iCO Verified Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delay in Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in myocardial ischaemia profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the Plasma Analyte Concentration Time Curve from Time 0 to Time of the Last Measurable Concentration [AUC (0-Last)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Analyte Concentration Time Curve from Time 0 to Infinite Time [AUC (0-Infinity)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of IV Lacosamide
Endpoint domain: Adverse events/effects
Primary endpoint: Time to return to previous activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to return to full work and household duties
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Plasmatic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in metabolic syndrome components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of HbA1c level (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Were Headache Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial Working Memory (SWM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spatial Span (SSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Working Memory Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavioral Regulation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: use of opioid (frequency, days of continuous abstinence)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in lifestyle measures (employment, relationships, behavioral problems, treatment engagement)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: incidence of device related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of oliguria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of gastric bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24-hour Intraocular pressure pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: liver fat fraction evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IOP Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Bupivacaine Analgesic concentration preserving quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of heat intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-classic cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indexes of insulin secretion and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients in Clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spectroscopic appearance of muscle after exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24 weeks progression-free survival (PFS24w) rate
Endpoint domain: Mortality/survival
Primary endpoint: Mass balance of CRN00808
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability of CRN00808
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Sinuses That Require Post-operative Interventions (Propel Mini Cohort)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Sinuses That Require Post-operative Interventions (Propel Nova Cohort)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resting State Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Days of discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Presence of paroxysmal atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in parathormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fMRI BOLD responses to emotional regulation task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI BOLD resting state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in brain atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to First Manifestations of CNS Oxygen Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Response as Measured by Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hemodilution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central line-associated bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Any Suspected Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Seroconverted Subjects Against 2 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUCinf of ASP015K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ASP015K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Clinical Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Functional Outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary Neurocognitive Outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Excess Weight Loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Regulation (Toronto Alexithymia Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing